Interview with Philippe Ranty, Managing Director, Actavis France
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
Address: Centre d’Affaires la Boursidière BP 50, 92357 le Plessis-Robinson, France ,France
Tel: +33 1 40 83 77 77
Web: http://www.actavis.com/en/default.htm
Actavis is the fifth largest generics company worldwide. In France, Actavis has been present since acquiring Labo Torlan in 2007. The groups domestic strategy can be characterized by three elements: a large product offer, a new approach of quality and customer relationship management and a strong involvement in sustainable development.
Actavis serves the French market through its Actavis France, Arrow Generiques and Medis businesses. The Company develops, manufactures and distributes a broad portfolio of products, including generic drugs for retail and hospital markets, OTC, cosmetics and mature products.
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
France Alzheimer’s Joel Jaouen and Benoit Durand articulate a comprehensive strategic framework for addressing one of Europe’s most pressing healthcare challenges. With four decades of operational excellence, the organisation has…
With only a handful of patients affected by each condition, rare diseases present a unique set of scientific, medical, and economic challenges. At the heart of this complex landscape is…
Alexis Genin, CEO of Brain & Mind, discusses the strategic vision behind France’s first national hub for neuroscience product development. Established to overcome the fragmented landscape in neuroscience innovation, Brain…
Europe has a plasma problem. The continent is over-reliant on the US for plasma – donated, purified human blood liquid – which is a key component in several lifesaving drugs…
Professor Jean-Yves Blay stands as a distinguished figure in contemporary oncology, serving simultaneously as a practising medical oncologist, cancer researcher, and institutional leader. Currently director general of a comprehensive cancer…
Virginie Beaumeunier, head of France’s CEPS, brings deep expertise in competition law and economic regulation to pharmaceutical pricing. Her background—including roles at the Finance Inspectorate and Competition Authority—shapes her approach…
Professor Alain Puisieux, President of the Executive Board at Institut Curie, leads the renowned cancer centre through an integrated strategy combining cutting-edge research and patient care. With a scientific background…
Founded in 2017 as part of France’s national health export strategy, the French Healthcare Association brings together more than 300 members from across the health ecosystem to showcase and support…
Seven years after our last discussion, GREENTECH has expanded its international presence, reinforced its leadership in dermocosmetics, and deepened its role in pharmaceuticals. In this interview, CEO Jean-Yves Berthon reflects…
Fabien Riolet leads Polepharma, France’s leading pharmaceutical manufacturing network, driving industrial sovereignty and innovation across 460 member companies. Under his leadership, it has evolved into a strategic hub for manufacturing…
With demand for plasma-derived therapies rising steadily and Europe rethinking its biomanufacturing sovereignty, France’s LFB is quietly positioning itself for a leap onto the global stage. Backed by a EUR…
Etienne Tichit has dedicated over five years to steering Novo Nordisk France through a transformative period of unprecedented growth and strategic realignment. His tenure has been marked by bold industrial…
See our Cookie Privacy Policy Here
